When LTGO insiders can sell

…, or exchangeable for our common stock have entered into market standoff agreements with us and have entered or will enter into lock-up agreements under which we have agreed or will agree, subject to specific exceptions described in the section titled "Underwriting," not to offer, sell, or transfer such securities for 180 days following the date of this prospectus. We refer to such period as the lock-up period. Goldman Sachs & Co. LLC, Jefferies LLC and Leerink Partners LLC may, in their sole discretion and at any time or from time to time before the termination of the lock-up period release all or any portion of the securities subject to lock-up agreements. Moreover, after this offering, holders of an aggregate of 43,112,837 shares of our common stock will have rights, subject to specified conditions, to require us to file registration statements covering their share…

Common stock to be outstanding immediately after this offering 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full). Use of proceeds We estimate that the net proceeds to us from the sale of our common stock in this offering will be approximately $315.7 million (or approximately $363.9 million if the underwriters exercise their option to purchase additional shares in full), based on the initial public offering price of $18.00 per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.

Rule 10b5-1 Sales Plans Our directors and executive officers may adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, without further direction from them. The director or executive officer may amend a Rule 10b5-1 plan in some circumstances and may terminate a Rule 10b5-1 plan at any time.

…ally all of our capital stock and securities convertible into or 240 Table of Contents exchangeable for our common stock with respect to the transfer, distribution or disposition of Lock-Up Securities (i) as one or more bona fide gifts or charitable contributions, or for bona fide estate planning purposes, (ii) upon death by will, testamentary document or intestate succession, (iii) if the lock-up party is a natural person, to any member of the lock-up party's immediate family or to any trust for the direct or indirect benefit of such lock-up party or the immediate family of such lock-up party or, if such lock-up party is a trust, t…

…iatrists and chiropractors), certain non-physician practitioners (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insu…

See the section titled "Underwriting—Directed Share Program" for additional information. The underwriters expect to deliver the shares against payment in New York, New York on August 10, 2026. Goldman Sachs & Co. LLC Jefferies Leerink Partners Guggenheim Securities Prospectus dated August 6, 2026 Table of Contents TABLE OF CONTENTS Page Prospectus Summary 1 Risk Factors 17 Special Note Regarding Forward-Looking Statements 100 Market, Industry and Other…

…ing effect to the Preferred Stock Conversion and Convertible Notes Conversion (each as defined below) in connection with the closing of this offering, and excludes: 9,852,834 shares of our common stock issuable upon the exercise of stock options outstanding under the 2019 Stock Plan (the 2019 Plan) as of March 31, 2026, with a weighted-average exercise price of $3.51 per share; 240,107 shares of our common stock issuable upon the exercise of stock options outstanding under the 2019 Plan subsequent to March 31, 2026, with a weighted-average exercise price of $8.16 per share; 533,013 shares of our common stock issuable upon the exerci…